168 related articles for article (PubMed ID: 24389062)
1. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model.
Andoh T; Fujimoto T; Sudo T; Suzuki M; Sakurai Y; Sakuma T; Moritake H; Sugimoto T; Takeuchi T; Sonobe H; Epstein AL; Fukumori Y; Ono K; Ichikawa H
Appl Radiat Isot; 2014 Jun; 88():59-63. PubMed ID: 24389062
[TBL] [Abstract][Full Text] [Related]
2. Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.
Andoh T; Fujimoto T; Sudo T; Fujita I; Imabori M; Moritake H; Sugimoto T; Sakuma Y; Takeuchi T; Kawabata S; Kirihata M; Akisue T; Yayama K; Kurosaka M; Miyatake S; Fukumori Y; Ichikawa H
Appl Radiat Isot; 2011 Dec; 69(12):1721-4. PubMed ID: 21367607
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies.
Fujimoto T; Andoh T; Sudo T; Fujita I; Imabori M; Moritake H; Sugimoto T; Sakuma Y; Takeuchi T; Sonobe H; Epstein AL; Akisue T; Kirihata M; Kurosaka M; Fukumori Y; Ichikawa H
Appl Radiat Isot; 2011 Dec; 69(12):1713-6. PubMed ID: 21354804
[TBL] [Abstract][Full Text] [Related]
4. Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: Trial using a lung metastasis model of CCS.
Andoh T; Fujimoto T; Suzuki M; Sudo T; Sakurai Y; Tanaka H; Fujita I; Fukase N; Moritake H; Sugimoto T; Sakuma T; Sasai H; Kawamoto T; Kirihata M; Fukumori Y; Akisue T; Ono K; Ichikawa H
Appl Radiat Isot; 2015 Dec; 106():195-201. PubMed ID: 26337135
[TBL] [Abstract][Full Text] [Related]
5. Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model.
Fujimoto T; Andoh T; Sudo T; Fujita I; Moritake H; Sugimoto T; Sakuma T; Akisue T; Kawabata S; Kirihata M; Suzuki M; Sakurai Y; Ono K; Fukumori Y; Kurosaka M; Ichikawa H
Appl Radiat Isot; 2013 Mar; 73():96-100. PubMed ID: 23306161
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
[TBL] [Abstract][Full Text] [Related]
7. Delivery of (10)boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy.
Obayashi S; Kato I; Ono K; Masunaga S; Suzuki M; Nagata K; Sakurai Y; Yura Y
Oral Oncol; 2004 May; 40(5):474-82. PubMed ID: 15006618
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases.
Trivillin VA; Garabalino MA; Colombo LL; González SJ; Farías RO; Monti Hughes A; Pozzi EC; Bortolussi S; Altieri S; Itoiz ME; Aromando RF; Nigg DW; Schwint AE
Appl Radiat Isot; 2014 Jun; 88():94-8. PubMed ID: 24360862
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.
Dagrosa MA; Viaggi M; Rebagliati RJ; Batistoni D; Kahl SB; Juvenal GJ; Pisarev MA
Mol Pharm; 2005; 2(2):151-6. PubMed ID: 15804189
[TBL] [Abstract][Full Text] [Related]
10. Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer.
Dagrosa MA; Thomasz L; Longhino J; Perona M; Calzetta O; Blaumann H; Rebagliati RJ; Cabrini R; Kahl S; Juvenal GJ; Pisarev MA
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1059-66. PubMed ID: 17967301
[TBL] [Abstract][Full Text] [Related]
11. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
[TBL] [Abstract][Full Text] [Related]
12. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy.
Ferrari C; Zonta C; Cansolino L; Clerici AM; Gaspari A; Altieri S; Bortolussi S; Stella S; Bruschi P; Dionigi P; Zonta A
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S341-4. PubMed ID: 19394838
[TBL] [Abstract][Full Text] [Related]
13. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST).
Fujimoto T; Andoh T; Sudo T; Fujita I; Fukase N; Takeuchi T; Sonobe H; Inoue M; Hirose T; Sakuma T; Moritake H; Sugimoto T; Kawamoto T; Fukumori Y; Yamamoto S; Atagi S; Sakurai Y; Kurosaka M; Ono K; Ichikawa H; Suzuki M
Appl Radiat Isot; 2015 Dec; 106():220-5. PubMed ID: 26278348
[TBL] [Abstract][Full Text] [Related]
14. Boron neutron capture therapy for undifferentiated thyroid carcinoma: preliminary results with the combined use of BPA and BOPP.
Viaggi M; Dagrosa MA; Longhino J; Blaumann H; Calzetta O; Kahl SB; Juvenal GJ; Pisarev MA
Appl Radiat Isot; 2004 Nov; 61(5):905-9. PubMed ID: 15308166
[TBL] [Abstract][Full Text] [Related]
15. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: combined administration of BSH and BPA.
Garabalino MA; Heber EM; Monti Hughes A; Pozzi EC; Molinari AJ; Nigg DW; Bauer W; Trivillin VA; Schwint AE
Appl Radiat Isot; 2014 Jun; 88():64-8. PubMed ID: 24360859
[TBL] [Abstract][Full Text] [Related]
16. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy.
Dagrosa MA; Viaggi M; Kreimann E; Farías S; Garavaglia R; Agote M; Cabrini RL; Dadino JL; Juvenal GJ; Pisarev MA
Thyroid; 2002 Jan; 12(1):7-12. PubMed ID: 11838734
[TBL] [Abstract][Full Text] [Related]
17. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA-BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch.
Aromando RF; Trivillin VA; Heber EM; Pozzi E; Schwint AE; Itoiz ME
Oral Oncol; 2010 May; 46(5):355-9. PubMed ID: 20308008
[TBL] [Abstract][Full Text] [Related]
18. Effects of boron neutron capture therapy on human oral squamous cell carcinoma in a nude mouse model.
Kamida A; Obayashi S; Kato I; Ono K; Suzuki M; Nagata K; Sakurai Y; Yura Y
Int J Radiat Biol; 2006 Jan; 82(1):21-9. PubMed ID: 16546900
[TBL] [Abstract][Full Text] [Related]
19. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.
Monti Hughes A; Heber EM; Pozzi E; Nigg DW; Calzetta O; Blaumann H; Longhino J; Nievas SI; Aromando RF; Itoiz ME; Trivillin VA; Schwint AE
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S313-7. PubMed ID: 19376711
[TBL] [Abstract][Full Text] [Related]
20. Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment.
Carpano M; Perona M; Rodriguez C; Nievas S; Olivera M; Santa Cruz GA; Brandizzi D; Cabrini R; Pisarev M; Juvenal GJ; Dagrosa MA
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):344-52. PubMed ID: 26232853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
